Previous 10 | Next 10 |
Through ongoing collaboration with Sanofi, Charles River will explore use of Virtual Control Groups in nonclinical toxicology Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi. The companies a...
2024-05-31 04:44:45 ET Summary The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River Laboratories is a promising investment in this industry, with...
Fast Track and Modular frameworks facilitate product development continuity via seamless process transfer to the Company’s viral vector Center of Excellence Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track v...
2024-05-09 19:00:06 ET Elizabeth Anderson from Evercore ISI issued a price target of $265.00 for CRL on 2024-05-09 16:15:00. The adjusted price target was set to $265.00. At the time of the announcement, CRL was trading at $230.09. The overall price target consensus is a...
2024-05-09 16:46:02 ET More on Charles River Laboratories Charles River Laboratories International, Inc. (CRL) Q1 2024 Earnings Call Transcript Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold' Read the full article on Seeking ...
2024-05-09 12:35:25 ET Charles River Laboratories International, Inc. (CRL) Q1 2024 Results Conference Call May 09, 2024 8:30 AM ET Company Participants Todd Spencer - VP, IR Jim Foster - Chair, President & CEO Flavia Pease - EVP, CFO Conference Call Pa...
2024-05-09 07:14:14 ET More on Charles River Laboratories Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold' Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript Charles River Laboratories Q1 2024 ...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
– First-Quarter Revenue of $1.01 Billion – – First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE: CRL) today rep...
2024-05-08 11:40:40 ET More on Charles River Laboratories Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold' Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript Charles River, Axovia to collaborat...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract...
2024-06-18 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector productio...